Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
暂无分享,去创建一个
C. Cetrulo | D. Ting | B. Blazar | M. Maus | S. Demehri | Bryan D Choi | Amanda A Bouffard | R. Larson | Amanda A. Bouffard | Lauren S. Riley | A. Boroughs | Erik B. Schiferle | Anupriya S. Kulkarni
[1] Matthew J. Frigault,et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. , 2018, Blood.
[2] M. Sadelain,et al. Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.
[3] D. Hafler,et al. Regulatory T cells in autoimmune disease , 2018, Nature Immunology.
[4] M. Ansari,et al. A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants , 2018, Scientific Reports.
[5] C. June,et al. CAR T cell immunotherapy for human cancer , 2018, Science.
[6] W. Haining,et al. Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells , 2018, Proceedings of the National Academy of Sciences.
[7] Jörn Walter,et al. CD137+CD154− Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures , 2018, Front. Immunol..
[8] Ying Hu,et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance , 2017, Science Translational Medicine.
[9] M. Levings,et al. Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells , 2017, Front. Immunol..
[10] J. Orange,et al. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. , 2017, Cell reports.
[11] F. Vincenti,et al. Transplant trials with Tregs: perils and promises. , 2017, The Journal of clinical investigation.
[12] F. Watt,et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] S. Riddell,et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy , 2017, Leukemia.
[14] D. Scott,et al. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. , 2017, Blood.
[15] J. Bluestone,et al. Regulatory T cell therapy for type 1 diabetes: May the force be with you. , 2016, Journal of autoimmunity.
[16] M. Levings,et al. How antigen specificity directs regulatory T‐cell function: self, foreign and engineered specificity , 2016, HLA.
[17] M. Levings,et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. , 2016, The Journal of clinical investigation.
[18] C. Le,et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. , 2016, Blood.
[19] Brian Keith,et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.
[20] Jeffrey A. Bluestone,et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells , 2015, Science Translational Medicine.
[21] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[22] R. Kaplan,et al. 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors , 2015, Nature Medicine.
[23] Na Li,et al. Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.
[24] S. Sakaguchi,et al. TREG-cell therapies for autoimmune rheumatic diseases , 2014, Nature Reviews Rheumatology.
[25] B. Falini,et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. , 2014, Blood.
[26] Jonathan H. Esensten,et al. microRNA-17–92 Regulates IL-10 Production by Regulatory T Cells and Control of Experimental Autoimmune Encephalomyelitis , 2013, The Journal of Immunology.
[27] D. Bigner,et al. Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody , 2013, Cancer Immunology Research.
[28] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[29] E. Shevach. Application of IL-2 therapy to target T regulatory cell function. , 2012, Trends in immunology.
[30] W. Kastenmuller,et al. Foxp3+ Regulatory T-cells and IL-2: The Moirai of T-cell Fates? , 2012, Front. Immun..
[31] D. Vignali. Mechanisms of Treg Suppression: Still a Long Way to Go , 2012, Front. Immun..
[32] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[33] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[34] J. Spencer,et al. Antibodies to human IL-10 neutralize ebvIL-10-mediated cytokine suppression but have no effect on cmvIL-10 activity. , 2010, Virus research.
[35] K. Wood,et al. In vivo Prevention of Transplant Arteriosclerosis by ex vivo Expanded Human Regulatory T Cells , 2010, Nature Medicine.
[36] T. Kelley,et al. Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway , 2009, BMC Immunology.
[37] T. Schumacher,et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis , 2009, Proceedings of the National Academy of Sciences.
[38] S. Sakaguchi,et al. Regulatory T cells: how do they suppress immune responses? , 2009, International immunology.
[39] D. Campana,et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[40] J. Sprent,et al. In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression , 2009, The Journal of experimental medicine.
[41] J. Wagner,et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. , 2008, Blood.
[42] D. Vignali,et al. How regulatory T cells work , 2008, Nature Reviews Immunology.
[43] T. Ley,et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. , 2007, Immunity.
[44] X. Wang,et al. Agonistic Anti‐4‐1BB Antibody Promotes the Expansion of Natural Regulatory T Cells While Maintaining Foxp3 Expression , 2007, Scandinavian journal of immunology.
[45] S. Larson,et al. Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.
[46] Alexander Perl,et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. , 2006, Blood.
[47] David C. Gondek,et al. Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism1 , 2005, The Journal of Immunology.
[48] T. Malek,et al. Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.
[49] Ethan M. Shevach,et al. Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function , 2004, The Journal of Immunology.
[50] J. Bae,et al. 4‐1BB‐dependent inhibition of immunosuppression by activated CD4+CD25+ T cells , 2004, Journal of leukocyte biology.
[51] C. Fathman,et al. Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.
[52] David Klatzmann,et al. CD4+CD25+ Immunoregulatory T Cells , 2002, The Journal of experimental medicine.
[53] B. Blazar,et al. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.
[54] J. Bluestone,et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.
[55] M. Toda,et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.
[56] E. Shevach,et al. CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.
[57] Z. Eshhar,et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[58] Arthur Weiss,et al. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways , 1991, Cell.
[59] S. Sakaguchi. Regulatory T cells: history and perspective. , 2011, Methods in molecular biology.
[60] Z. Eshhar,et al. The T-body approach: potential for cancer immunotherapy , 2004, Springer Seminars in Immunopathology.